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Clinically-relevant pituitary adenomas occur 
with a prevalence of approximately 1 per 1000 
population in Belgium.  Pituitary adenomas that 
occur in families are likely to have an important 
genetic pathophysiological basis.  Currently about 
5% of all pituitary adenoma cases have a family 
history of pituitary adenomas, classically due to 
multiple endocrine neoplasia type 1 (MEN1) and 
Carney complex (CNC).  Over the last decade we 
have described non-MEN1/CNC familial pituitary 
tumours that include all tumour phenotypes, 
a condition named ‘familial isolated pituitary 
adenoma’ (FIPA). Clinical features of FIPA differ 
from those of sporadic pituitary adenomas in that 
patients with FIPA are often younger and have larger 
tumours at diagnosis. Approximately 15% of FIPA 
patients have mutations in the aryl hydrocarbon 
receptor interacting protein gene (AIP), which 
indicates that FIPA may have a diverse genetic 
pathophysiology.  In this review we examine new 
ﬁ ndings on the epidemiology of pituitary adenomas, 
we review familial causes of pituitary adenomas 
with a particular emphasis on modern clinical 
testing.  In addition the clinical and genetic features 
of FIPA are described in terms of FIPA representing a 
useful framework to study the features of pituitary 
adenomas that occur in a familial setting.
EPIDEMIOLOGY OF PITUITARY TUMOURS:
UPDATE
While many molecular genetic abnormalities have 
been recognized in the setting of anterior pituitary 
adenomas, the aetio-pathophysiology of these tumours 
continues to provoke interest.  Some of this interest 
stems from the growing realization that clinically-rel-
evant pituitary adenomas are considerably more 
prevalent than previously thought and that these tu-
mours are associated with clinical challenges in terms 
of symptoms and their complex management.  His-
torically, there has been uncertainty regarding the 
prevalence of pituitary tumours, with a disconnect 
between autopsy/radiological series and clinical data. 
Assessments based on unselected autopsy or MRI data 
suggest that anterior pituitary adenomas occur fre-
quently.  In a meta-analysis, Ezzat et al suggested a 
mean pituitary tumour prevalence of 14.4% and 22.5% 
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in autopsy and radiological series, respectively (1).  In 
contrast, population epidemiological studies performed 
previously indicated that pituitary tumours occur infre-
quently, at a rate of 190–280 cases/million (1:3571 to 
1:5263 individuals) (2).  Between these two extremes 
lies the clinically relevant information, namely the 
prevalence of clinically-apparent pituitary tumours. 
Recently, we reported some of the ﬁ rst evidence regard-
ing clinically-apparent pituitary adenoma prevalence in 
the modern era.  These new data suggests that pituitary 
adenomas occur relatively frequently in the general 
population, with an overall rate of one case in 1064 of 
the population (3).  This study in a population of near-
ly 72,000 demonstrated that clinically apparent pitu-
itary adenomas had a prevalence that was 3.5 to 5 times 
higher than that estimated previously.  These results 
from the Province of Liège in Belgium appear to be of 
relevance to countries with a similarly developed social 
and health system.  The study probably represents an 
under-estimation of the number of clinically-active 
pituitary adenomas, as it was not a screening study but 
a cross-sectional case-ﬁ nding study.  Screening studies 
are, however, not possible in a population of this mag-
nitude (>70,000 people); indeed the identiﬁ cation of 
sub-clinical micro-incidentalomas is of questionable 
relevance.
A prevalence of about one pituitary adenoma per 
thousand people is a ﬁ nding that could have many 
practical implications.  Firstly, increased tumour preva-
lence can occur due to increased incidence, increased 
survival or both.  Evidence suggests that the underlying 
rate of occurrence of adenomas today is unchanged as 
compared with older studies (4).  Hence, increased 
prevalence is likely to be due to a combination of more 
thorough recognition of cases once they have occurred 
and greater life expectancy in affected patients.  No 
data are available to support the contention that pitu-
itary adenoma patients are living longer in general.  A 
greater understanding of the impact of disease control 
on mortality in acromegaly and Cushing’s disease, allied 
with improved neurosurgical and medical care are 
likely to have had a beneﬁ cial effect on survival and, in 
turn, prevalence.  However, probably the most likely 
reason for the increased prevalence of pituitary adeno-
mas seen in the Liège study was the nature of the 
methodology.  The intensive, case-ﬁ nding approach in 
concert with local medical practitioners increased the 
yield of relevant cases for inclusion beyond that ob-
tained in only referral hospital-based studies.  
Disease prevalence rates are required to assess the 
“burden of disease” in a given population. When calcu-
lations of health care or research budget allocations are 
made, these are usually done with some consideration 
of the frequency of the disease in the community.  Pi-
tuitary adenomas, although almost never malignant, 
can have important attendant costs.  The effects of 
untreated pituitary adenomas are also signiﬁ cant in 
terms of added morbidity due to hormonal hyper- or 
hypo-secretion.  Pituitary microadenomas are more 
likely to beneﬁ t from curative neurosurgery than larger 
adenomas, making earlier diagnosis and treatment 
desirable.  For patients not cured by surgery, lifelong 
medical therapy may be required to reduce hormonal 
hypersecretion or to replace hormonal deﬁ ciencies in 
other pituitary axes.  Regular follow-up of pituitary 
tumour size using MRI is recommended for clinically-
apparent pituitary adenomas if cure has not been 
achieved.  Treatment-resistant pituitary tumours will 
require multimodal therapy that also includes radio-
therapy.  Taken together these facts indicate that a 
patient with a pituitary tumour may accumulate sig-
niﬁ cant costs over the course of treatment.  
GENETICS OF PITUITARY TUMOURS: UPDATE
MEN1, Carney Complex and MEN4
The evidence suggesting that clinically apparent 
pituitary adenomas are 3- to 5-times more common 
than previously thought increases the need to under-
stand the pathophysiological mechanisms that give rise 
to these tumours. A wealth of studies has been per-
formed on the molecular genetics of pituitary adenomas 
in an effort to determine their pathophysiology.  Muta-
tions in a series of genes, some relatively frequent and 
some rare, have been described and characterized in the 
experimental setting.  Chief among these is the gsp gene 
that encodes the alpha subunit of the Gs, a heterotri-
meric G-protein.  Activating mutations in gsp lead to 
constitutive activation of Gs? and increased adenylyl 
cyclase activity and overproduction of cAMP.  Up to 
40% of somatotropinomas have mutations in gsp (5). 
Pituitary adenomas with heritable genetic causes 
are rare and have been described most often in the set-
ting of multiple endocrine neoplasia type 1 (MEN1) and 
Carney complex (CNC). MEN1 is an autosomal domi-
nant condition that is associated with the occurrence 
of parathyroid, enteropancreatic and anterior pituitary 
tumours (6).  Endocrine-inactive tumours, such as, lipo-
mas and angioﬁ bromas are also frequently seen in 
MEN1 patients. The MEN1 gene on chromosome 11q13 
(7) encodes the nuclear protein, menin (8). MEN1 ap-
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pears to act as a tumour suppressor gene, and recent 
data suggest that menin can potentially interact with 
thousands of genes, 3’ sites and in chromatin (9, 10). To 
date, over 500 different individual mutations in the 
MEN1 gene have been described (11), most of which 
predict a truncated menin protein. However, in 20-30% 
of cases suggestive clinically of MEN1, the sequence is 
normal.  About 40% of patients with MEN1 have pitu-
itary adenomas, and 17% of cases present with a pitu-
itary tumour (12, 13).  Such patients who presented 
with a pituitary adenoma did so 7 years before patients 
presented with enteropancreatic lesions. Among famil-
ial MEN1 cases, pituitary disease was signiﬁ cantly more 
frequent than in non-familial MEN1 cases (59% versus 
34%, respectively).  Females with MEN1 have a some-
what increased chance of having a pituitary adenoma. 
Prolactinomas predominate among both MEN1 associ-
ated and non-MEN1 pituitary adenomas, and the pro-
portions of prolactinomas, GH-secreting, ACTH-secret-
ing, non-secreting and co-secreting adenomas are 
similar between the MEN1 and non-MEN1 patients. 
MEN1-related prolactinomas are predominantly mac-
roadenomas (84%) and higher rates of invasion are seen 
than in non-MEN1 prolactinomas.  The response of 
MEN1-related prolactinomas to dopamine agonists is 
poor, with only 44% of patients being normalized.  Pi-
tuitary tumours in MEN1 appear to be larger and more 
aggressive than in patients without MEN1 (8), with 
macroadenomas being present in 85% of the former, 
compared with only 42% of the sporadic cases.  MEN1-
associated pituitary tumours are signiﬁ cantly more 
likely to cause signs due to tumour size and have a 
signiﬁ cantly lower rate of hormonal normalization than 
non-MEN1 pituitary tumours. 
Somatic mutations of the MEN1 gene are not an 
important factor in the tumourigenesis of non-MEN1 
sporadic pituitary adenomas (14, 15). Theodoropoulou 
et al found that menin was detectable in 67768 spo-
radic non-MEN1 pituitary tumours (16). There is no 
recognized relationship between the site or type of 
genetic mutation in the MEN1 gene and the expressed 
MEN1 disease phenotype, although disease clustering 
and variations in severity have been recognized (17). 
Such clusters include the “prolactinoma variant” seen 
in kindreds from the Burin peninsula in Canada (MEN-
1BURIN) (18, 19). MEN1 has been recognized clinically 
for some time and consensus guidelines for its investi-
gation and management have been developed (20). 
Advances in the availability of DNA testing may allow 
for some practical simpliﬁ cation.  Assessment of which 
patients to test for MEN1 germline mutations depends 
on their meeting the criteria for the disease (practi-
cally, 2 of the 3 constituent major affected tissues: 
parathyroid, enteropancreatic or pituitary tumours). 
Assessment of family history is also useful to detect 
previously unrecognized contributory information, 
however, it is often practically difﬁ cult to exclude a 
familial case of MEN1 in small kindreds with few living 
relatives.  For index cases in which MEN1 is suspected 
as a cause for their pituitary tumour, germline DNA 
analysis of the MEN1 gene would be recommended. In 
the case where a MEN1 mutation is found, then full 
family screening for clinical features and biochemical 
abnormalities (particularly hypercalcaemia) is a good 
ﬁ rst step.  Carriers should be followed closely with 
regular biochemical, endocrine and appropriate radio-
logical screening for nascent tumours. 
CNC is rare with about 500 cases reported to date 
(21).  The primary genetic cause of CNC is mutation of 
the protein kinase A regulatory subunit 1A gene (PRKA-
R1A) on chromosome 17q22-24 (22). CNC, usually 
familial, consists of patients with a complex of skin 
pigmentation, cardiac myxomas, endocrine hypersecre-
tion and schwannomas (23).  The main endocrine ab-
normalities seen in CNC are primary pigmented nodu-
lar adrenocortical disease (PPNAD), thyroid tumours 
and nodules, testicular tumours (large cell calcifying 
Sertoli cell tumour (LCCSCT), Leydig cell tumours) and 
acromegaly due to a pituitary adenoma (24).  Acro-
megaly itself is uncommon in CNC (10% of cases), but 
about 75% of patients exhibit asymptomatic elevations 
in GH, IGF-1 or prolactin levels, or abnormal responses 
to dynamic pituitary testing.  An important feature of 
CNC-related acromegaly is multifocal hyperplasia of 
somatomammotropic cells that included non-adeno-
matous pituitary tissue within the tumours of CNC 
patients.  The zones of hyperplasia were not well de-
marcated and exhibited increased cellularity and altered 
reticulin staining that merged with normal pituitary 
tissue.  No consistent genetic abnormalities were seen 
on comparative genome hybridization.  Electron micros-
copy showed that tumours from acromegalic patients 
with CNC demonstrate an heterogeneous intracellular 
structure (25).  Acromegaly in CNC develops insidi-
ously and may begin in apparently normal somatomam-
motrope tissue that undergoes multifocal hyperplasia 
to form GH/prolactin-secreting adenomas. As in MEN1, 
sporadic pituitary tumours do not exhibit somatic mu-
tations the PRKAR1A gene (26).
A MEN-1 like syndrome (MEN-4) has been reported 
recently in rats and in humans and relates to mutations 
in the CDKN1B gene that encodes p27kip1 (27, 28). To 
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date only one family with acromegaly, hyperparathy-
roidism, and renal and testicular cancer has been 
 reported and a further sporadic case with Cushing’s 
disease, a cervical carcinoid tumour, and hyperparathy-
roidism has been reported (29).  MEN4 is a very rare 
condition and testing remains in the investigational 
setting.  
Familial Isolated Pituitary Adenomas (FIPA)
Pituitary tumours of all types can occur in multiple 
members of a single kindred in the absence of MEN1/
CNC, a condition termed familial isolated pituitary 
adenomas (FIPA). To date we have identiﬁ ed >130 FIPA 
kindreds in our collaborative series (30), and FIPA 
families have been reported also by separate research 
groups (31, 32). Mutations in the aryl hydrocarbon re-
ceptor interacting protein gene (AIP) in familial acro-
megaly kindreds have explained the pathophysiology 
of a proportion of cases. FIPA is not limited to the phe-
notype of acromegaly, and represents a clinical frame-
work for further genetic study.
In FIPA, pituitary tumours of the same type can pres-
ent in all affected family members (homogeneous 
presentation), or affected members can have different 
types of tumours (heterogeneous presentation).  In an 
international study performed from 2000 to 2005, we 
identiﬁ ed a total of 64 FIPA families (33). To date, FIPA 
kindreds with up to four affected members (i.e. subjects 
with pituitary tumours) have been described. The cohort 
is comprised equally of families with homogeneous and 
heterogeneous tumour types in affected members. The 
frequencies of the various different tumour types in 
FIPA are: prolactinoma (41%), somatotropinoma (30%), 
non-secreting tumour (13%), somatolactotropinoma 
(7%), gonadotropinoma (4%), Cushing’s disease (4%) 
and thyrotropinoma (1%). First-degree relationship 
between affected members within families occurs in 
approximately 75% of FIPA families.  FIPA patients pres-
ent with pituitary tumours 4 years earlier than their 
sporadic counterparts.  In families with multiple af-
fected generations, the children/grandchildren pre-
sented signiﬁ cantly earlier (20 years) than their par-
ents/grandparents. Macroadenomas are seen in 63% of 
cases in FIPA kindreds.  In terms of speciﬁ c tumour types, 
prolactinomas in FIPA are mainly microadenomas oc-
curring in women, while males invariably have macroad-
enomas; which largely reﬂ ects the characteristics of 
sporadic prolactinomas (34).  Prolactinomas in hetero-
geneous FIPA have higher rates of extension and inva-
sion as compared with sporadic cases.  In somatotropi-
noma patients from FIPA families, half occur as 
homogeneous acromegaly (familial acromegaly) fami-
lies, and 50% in combination with other tumour types 
(heterogeneous families).  Non-secreting pituitary tu-
mours occur in heterogeneous FIPA families and are 
diagnosed 8 years earlier and have a higher rate of 
extension/invasion than sporadic tumours. Gonadotro-
pinomas and Cushing’s disease can occur rarely in a 
homogeneous FIPA setting.
In 2006, Vierimaa et al reported the results of a 
comprehensive genetic study that identiﬁ ed mutations 
in the aryl hydrocarbon receptor interacting protein 
(AIP) gene as being associated with the familial presen-
tation of somatotropinomas and prolactinomas (35). 
Loss of heterozygosity at the AIP locus in tumour 
samples indicated that these tumours had lost the func-
tion of the normal allele in a “second hit” according to 
the Knudson model.  Other families tested negative for 
AIP mutations.  In the FIPA cohort we studied 73 FIPA 
families from nine countries, and 15% of the cohort had 
germline mutations in AIP (36).  Ten separate mutations 
were found, one of which (R304X) was found in a FIPA 
family that is apparently unrelated to a family from the 
same country (Italy) with the same mutation reported 
by Vierimaa et al. Patients with AIP mutations were 
signiﬁ cantly younger at diagnosis (12 years) than FIPA 
patients without AIP mutations.  Tumours were larger 
in the AIP mutation-positive groups versus the remain-
der of the cohort.  Only 50% of those with homoge-
neous acromegaly had AIP mutations.  Importantly, 
kindreds with strong familiality for pituitary tumours 
(3 or 4 affecteds) can be negative for mutations in AIP 
(and CDKN1B), which indicates strongly that other 
genes may be involved in the causation of FIPA.
Further analysis of the disease characteristics of FIPA 
patients with AIP mutations indicates that tumour and 
hormonal data are heterogeneous.  Over 60% of AIP 
mutation positive patients with somatotropinomas had 
increased GH/IGF-I only and remaining 38% also had 
elevated prolactin.  Somatotropinoma patients with AIP 
mutations can be immunohistochemically positive for 
GH alone (59%), GH and prolactin (33%) or GH and 
FSH (8%).  
Since these initial studies, many AIP mutations have 
been described in the FIPA setting (Figure 1).  FIPA 
families with AIP mutations have also been reported by 
other groups (37, 38). A Q14X mutation, although found 
with high frequency in Finland, was not found in popu-
lations of sporadic adenomas from across the world 
indicating it as a founder mutation (39).  Sporadic pi-
tuitary tumour patients infrequently have AIP muta-
tions, although they are not entirely absent (40). Over-
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all, sporadic pituitary tumour patients with AIP 
mutations seem to present at a young age and mainly 
with somatotropinomas, although other pituitary tu-
mour types do occur (41). Cazabat et al reported that 
in a total of 154 sporadic patients with acromegaly, ﬁ ve 
patients (3.2%) demonstrated AIP mutations.  Studies 
in other tumours have revealed no ﬁ rm evidence of 
germline AIP mutations as a potentially causative or 
contributory factor (42).
The manner by which AIP mutations cause pituitary 
adenomas in FIPA and apparently sporadic cases is 
largely unknown. Many AIP mutations described to date 
would involve truncations of the AIP protein, with the 
loss of a tetratricopeptide repeat domain and the car-
boxy terminal that are important for interactions with 
other proteins such as heat shock protein 90 (hsp90) 
and the aryl hydrocarbon receptor (43, 44, 45, 46, 47). 
Other missense mutations (e.g. R271W) involve highly 
conserved amino acids, which may alter AIP function in 
other ways.  Whether various mutated versions of AIP 
are actually expressed or undergo mRNA degradation 
is presently unknown   A variety of cellular effects are 
potentially related to AIP activity, of which modulation 
of phosphodiesterase PDE4A5 and phosphodiesterase 
PDE2A activities are of interest (48, 49). Leontiou and 
colleagues found that over-expression of wild-type AIP 
in HEK 293, human embryonic lung ﬁ broblast (TIG 3) 
and the rat somatomammotroph (GH3) cell lines led 
to marked reductions in measures of cell proliferation 
(32).  When a variety of mutated forms of AIP were 
expressed in the cell lines (including a number of muta-
tions described in the setting of FIPA), suppression of 
cell proliferation was negated.  Also protein-protein 
interactions between AIP and PDE4A5 were disrupted 
by mutations in AIP. Immunohistochemical data re-
vealed that in normal pituitary, AIP co-localized only 
with GH and prolactin secreting cells and was found in 
association with secretory granules. In sporadic tumours 
AIP protein is expressed in all tumour types, however, 
it was only expressed in cytoplasm in prolactinomas, 
non-functioning and Cushing disease tumours; AIP ap-
peared to co-localize with secretory granules in somato-
tropinomas. Study of Aip knockout models is at an 
early stage and no speciﬁ c information on pituitary 
status has been reported (50, 51).  Given the important 
role of AhR in mediating the biological effects on di-
oxin, the potential for pituitary tumourigenesis having 
its roots in environmental toxins has been suggested. 
Data from one of the most exhaustively studied indus-
trial accidents involving dioxin exposure would argue 
otherwise. Pesatori et al studied the incidence of pitu-
itary tumours in the Seveso population exposed to 
2,3,7,8-tetrachlorodibenzo-para-dioxin after an acci-
dent in 1976 (52). They found no signiﬁ cant increase in 
the incidence of pituitary tumours in this region, al-
though given the often indolent nature of pituitary 
adenoma formation may require longer follow up.  Fur-
thermore, a more intensive study of patients with very 
high clinical exposure to dioxins (e.g. those with chlor-
acne and high dioxin titers) may be useful to ﬁ nally 
discount the link between environmental dioxin expo-
sure and increased rates of pituitary tumourigenesis.
From a clinical perspective, it should be emphasized 
that clinically relevant pituitary adenomas are more 
common than previously thought (1:1000) and occur 
in a familial setting in about 5% of cases overall.  There-
fore, careful questioning regarding family history of 
pituitary disease should be part of the workup of all 
patients with pituitary adenomas. The discovery linking 
mutations in AIP to pituitary tumours occurring in a 
family setting has provided particularly important im-
petus, but the molecular pathophysiology remains very 
unclear.  Families bearing AIP mutations have more ag-
gressive pituitary tumours in affected members, and are 
often seen at a much younger age than is usual in the 
sporadic setting.  Genetic screening for AIP mutations 
in patients with sporadic pituitary adenomas and in 
relatives of those bearing AIP mutations requires care-
ful consideration. There remains divergence about the 
penetrance of pituitary adenomas among kindreds with 
Figure 1.  Mutations in the aryl hydrocarbon receptor interacting 
protein gene (AIP) reported in FIPA and sporadic pitui-
tary tumour patients (current September 2008).  FKBP-
PPI = FK506 binding protein-type peptidyl-prolyl cis-
trans isomerase; TPR = tetratricopeptide repeat domain; 
hsp90 = heat-shock protein 90; AhR = Aryl hydrocarbon 
receptor.
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AIP mutations, making the true risk of disease in muta-
tion carriers unclear.  We suggest that the penetrance 
of pituitary disease in AIP mutation-bearing FIPA kin-
dreds may be relatively high, at least 33% in the largest 
kindreds  (53).  For newly recognized FIPA families we 
would recommend initial sequencing of the full length 
of the AIP gene in at least one affected individual. This 
remains an investigational study that is not offered 
commercially at this time, although the relatively short 
length of the AIP gene makes sequencing relatively 
uncomplicated.  Sequencing of the AIP gene from so-
matic DNA in patients who have undergone pituitary 
neurosurgery is somewhat more complex but has led 
to the identiﬁ cation of AIP mutations using the multi-
plex ligation-dependent probe ampliﬁ cation analysis 
(MLPA) methodology.  MLPA of germline DNA is also 
useful for the initial identiﬁ cation of large genetic dele-
tions of the AIP gene or more extensive deletions includ-
ing the AIP gene (54).  In the case of relatives of patients 
with AIP mutation-related pituitary adenomas, we sug-
gest constructing a careful genealogical tree and under-
taking targeted germline AIP screening to identify 
carriers. As tumours in individuals with AIP mutations 
are more aggressive and occur at an earlier age, there 
is potential value in identifying carriers for the purpose 
of performing MRI and hormonal testing; the ultimate 
aim would be to diagnose tumours at as small a size as 
possible in order to permit potentially curative pituitary 
neurosurgical resection.  In the absence of a tumour on 
MRI, follow-up of mutation carriers can be performed 
on a regular basis (yearly), relying predominantly on 
clinical symptoms and basal hormonal tests (IGF-I and 
prolactin).
Widespread AIP screening in unselected patients 
with sporadic pituitary adenomas is not warranted at 
this time. Young patients with aggressive pituitary tu-
mours are also more likely to carry AIP mutations, and 
testing for AIP mutations among apparently sporadic 
populations should at this time be limited to such young 
cases.  
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